Cardiovascular Systems (NSDQ:CSII) today posted fourth-quarter results that missed the overall consensus on Wall Street.
The St. Paul, Minnesota-based heart device company reported losses of $9.69 million, or -25¢ per share, on sales of $62.5 million for the three months ended June 30, for a bottom-line loss of 83.3% on sales loss of 11.96% compared with Q4 2021.
Adjusted to exclude one-time items, earnings per share were -25¢, 3¢ behind The Street, where analysts were looking for sales of $62.97 million.
“During Q4, we achieved strong sequential growth across all business segments with our U.S. peripheral and coronary atherectomy franchises growing 9% and 16% over the prior quarter, respectively. International revenues grew 14% sequentially to $5 million,” CEO and President Scott Ward said in a news release.